Table 1. Eligibility criteria for the selection of sources included in the systematic review on effectiveness and safety of palivizumab.

Inclusion criteria

Exclusion criteria

• Studies conducted in humans  • Studies that included, either as the study population or as a subgroup analysis, infants and children who received palivizumab (SYNAGIS) according to approved indications  • Studies that reported on the safety, efficacy, and/or effectiveness of palivizumab  • Full-text articles, conference proceedings including abstracts and posters, or reports  • Original research articles, reviews, and meta-analyses (the latter two were used for snowballing only)  •For studies with multiple publications, only the latest publication on each outcome of interest was retained

• Off-label populations  • Case reports  • Letters to the editors and editorials  • Opinions  • Phase I and II clinical trials  • Nonclinical and experimental studies  • Studies reporting preliminary results (later published as full text)